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Clinical trials aiming to develop disease-altering drugs for Alzheimer’s disease (AD), a
neurodegenerative disorder with devastating consequences, are failing at an alarming
rate. Poorly defined inclusion-and outcome criteria, due to a limited amount of
objective biomarkers, is one of the major concerns. Non-invasive molecular imaging
techniques, positron emission tomography and single photon emission (computed)
tomography (PET and SPE(C)T), allow visualization and quantification of a wide variety of
(patho)physiological processes and allow early (differential) diagnosis in many disorders.
PET and SPECT have the ability to provide biomarkers that permit spatial assessment
of pathophysiological molecular changes and therefore objectively evaluate and follow
up therapeutic response, especially in the brain. A number of specific PET/SPECT
biomarkers used in support of emerging clinical therapies in AD are discussed in this
review.
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INTRODUCTION
The worldwide prevalence of AD is estimated at 35 million, a number expected to quadruple by
2050, due to the increasing lifespan of the world population (Brookmeyer et al., 2007). With an
unfavorable prognosis and a life expectancy of approximately 8–10 years, AD is becoming one
of the most costly diseases for society (Thies and Bleiler, 2013). In spite of increasing knowledge
Abbreviations: 5-HT, 5-hydroxytryptamine; 5-HTRs, 5-HT receptors; 5-HTT, 5-HT transporter; α-APP, α-amyloid
precursor protein; Aβ, amyloid beta; ACh, acetylcholine; AChE, acetylcholinesterase; AD, Alzheimer’s disease; ADAS-cog,
Alzheimer’s disease assessment scale-cognitive subscale; ALA, α-lipoic acid; APP, amyloid precursor protein; BACE1, β-site
APP-cleaving enzyme 1; BBB, blood–brain barrier; BPSD, behavioral and psychological symptoms of dementia; BZDs,
benzodiazepines; CBD, corticobasal degeneration; ChAT, choline acetyltransferase; CIBIC+, clinician’s interview-based
impression of change; CNS, central nervous system; CSF, cerebrospinal fluid; CT, computerized tomography; CTI, clinical
trial identifier; D1R, dopamine1-like receptors; DA, dopamine; DAT, dopamine transporter; DLB, dementia with Lewy bodies;
ECT, EudraCT-number; EMA, European medicines agency; FDA, food and drug administration; FTD, frontal temporal
dementia; GABA, gamma-amino butyric acid; GSK, glycogen synthase kinase; HCs, healthy controls; mAChR, muscarinic
acetylcholine receptor; MAPT, microtubule-associated protein tau gene; MCI, mild cognitive impairment; MMSE, mini-
mental state examination; MOAs, monoamine oxidases; MRI, magnetic resonance imaging; nAChRs, nicotinic acetylcholine
receptors; NFTs, neurofibrillary tangles; PBR, peripheral benzodiazepine receptor; PET, positron emission tomography; P-gp,
permeability glycoprotein; PHFs, paired helical filaments; PSP, progressive supranuclear palsy; p-tau, phosphorylated tau;
rCBF, regional cerebral blood flow; SERT, 5-HT reuptake transporter; SP, senile plaques; SPE(C)T, single photon emission
(computed) tomography; TSPO, translocator protein; VDAC, voltage dependent anion channel.
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about the genetics, epidemiology, and histopathological features
of AD there is, at this moment, only symptomatic treatment
available. However, already at early clinical signs, intrinsic disease
progression has developed for a long time; patients rapidly
decline and develop irrevocable brain damage (Masters et al.,
2006; Romano and Buratti, 2013). Therefore, there is a great
need for efficient treatment that should be initiated in a very
early phase of the disease. Strict definite diagnosis can still
only be made post-mortem, on the basis of two pathological
hallmarks: SP and NFTs (Hyman et al., 2012), although use of
biomarkers is strongly advocated in research guidelines (Dubois
et al., 2014). More than 90% of clinical trials aiming to intervene
at the causative pathological elements have failed to produce
disease altering effects. A major concern hereby is the lack of
objective biomarkers assisting in the evaluation of inclusion- and
outcome criteria of participating patients, as many participants
turned out to be misdiagnosed, particularly in the early AD
disease stages (Jack et al., 2010; Barthel et al., 2015; James et al.,
2015). Currently five biomarkers for AD have been used for
evaluation of disease and monitoring of disease progression
(Jack et al., 2010): CSF levels of Aβ42, CSF levels of total tau
and p-tau181 and p-tau231, structural imaging (CT and MRI)
and functional imaging (PET with [18F]FDG). Elevated levels of
CSF tau and reduced levels of CSF Aβ allow the prediction of,
respectively, the NFT load and the SP deposits (Ahmed et al.,
2014; de Souza et al., 2014; Wurtman, 2015). Therefore, these
CSF levels appear to be useful biomarkers in the diagnosis of
AD (Wallin et al., 2006; Weiner et al., 2015). Nonetheless, CSF
sampling requires an invasive lumbar puncture, quantification of
CSF levels is hampered by interlaboratory variability and CSF
values do not provide regional information on tau- and Aβ
deposits. The regional concentration of tau- and Aβ deposits is
however essential for a differential diagnosis of AD, especially
among the different tauopathies (Hampel and Teipel, 2004; Gozes
et al., 2009; Hampel et al., 2010). Structural volume measurement
can be used to measure regional cerebral atrophy. Although
not highly specific for AD due to overlap with ‘normal’ aging,
the degree of atrophy follows neuropathological progression in
AD and severity of volume loss correlates well with disease
progression (Masters et al., 2006; Jack et al., 2010). Regarding
the biomarkers that can be visualized and quantified by the
molecular imaging techniques PET and SPECT, there are three
important applications to be considered, that could contribute
to successful drug development in clinical trials. The first
one is the ability of PET and SPECT to provide quantitative
and spatial in vivo assessment of, for example, the amyloid-
and tau burden in AD patients. By doing so, inclusion and
exclusion criteria in clinical trials can be verified more objectively
than what was possible now with the previous biomarkers.
Indeed, the use of specific radiotracers, for various targets, may
provide accurate differential diagnosis (even at early AD stages)
and true confirmation of the availability of the drug target,
which allows physicians to reliably select patients for clinical
trials to evaluate novel AD therapeutics (Barthel et al., 2015).
Another important role for these molecular imaging techniques
is the assessment and quantitative follow-up of drugs aiming to
intervene at the specific molecular pathophysiological processes.
Using highly selective PET- or SPECT radioligands, the true
biological effect of novel clinical candidates can be established
and true quantitative assessment is possible (Barthel et al., 2015).
Thirdly, molecular imaging can be applied to measure the dose-
related occupancy of specific targets caused by drugs under test,
which allows the characterization of the optimal therapeutic
window and thus a more effective design of subsequent clinical
drug trials (Broich et al., 1998; Passchier et al., 2002). Although
PET is able to provide a much higher spatial resolution and
dynamic scanning with higher temporal resolution and better
quantification than SPECT, SPECT cameras are more widely
available and cheaper than PET cameras. Both the availability
and the economical aspect are important to consider when
performing large multi-center clinical trials (Rahmim and Zaidi,
2008).
The most frequently used PET radiopharmaceutical is
2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG, Figure 1), a
glucose derivative which allows measurement of brain glucose
metabolism directly related with viability of brain tissue in AD
(Barthel et al., 2015). This commercially available compound,
with various clinical applications, has been well established
in routine clinical practice, but also in the recruitment and
follow-up of the majority of AD clinical trials which use PET
as biomarker technique (Barthel et al., 2015). Indeed, several
AD clinical trials are currently recruiting and following up
patients with [18F]FDG (CTI: NCT02593318, NCT01561053,
and NCT02560753). Although FDG-PET is able to provide
information about regional glucose metabolism, which
can aid in the detection and prognosis of MCI for further
progression to AD, there is a great need for PET- and SPECT
radiopharmaceuticals which deliver more target-specific
information of a variety of (patho)physiological processes that
are happening in AD. In this review we will therefore focus on
some of the major molecular pathophysiological changes known
to occur in AD, along with emerging pharmacological treatment
approaches. Furthermore, specific attention will be attributed
to the role that PET- and SPECT biomarkers (can) play during
these clinical trials.
FIGURE 1 | Structure of [18F]FDG.
CHOLINERGIC HYPOTHESIS
Acetylcholinesterase
The cholinergic hypothesis states that a decreased cholinergic
neurotransmission, caused by a degeneration of cholinergic
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neurons in the basal forebrain, leads to several cognitive and
functional conditions, associated with the symptoms of AD
(Davies and Maloney, 1976; Bartus et al., 1982). Furthermore, the
disruption of AChE seems to be associated with NFT- and Aβ
deposits (Tavitian et al., 1993).
Acetylcholine, a neurotransmitter synthesized presynaptically
by ChAT, is released in the synaptic cavity, where it is able
to interact with nicotinic and muscarinic cholinergic receptors
on pre- and postsynaptic membranes. Synaptic transmission is
eventually stopped by the hydrolysis of ACh by AChE (Lleo et al.,
2006). Both ChAT and AChE expression is reduced in cortical
regions of AD patients (Davies and Maloney, 1976; Coyle et al.,
1983; Vogels et al., 1990).
Inhibition of AChE was the first approach to treat AD, and
this led to the FDA approval of eventually four AChE inhibitors:
galantamine, rivastigmine, donepezil, and tacrine, though the
latter one was largely discontinued due to hepatotoxicity issues
(Wu et al., 2010). All inhibitors showed however only mild
symptomatic improvement in patients with mild to moderate
AD (Burns et al., 1999; Rosler et al., 1999; Farlow et al., 2000;
Greenberg et al., 2000; Raskind et al., 2000; Tariot et al., 2000;
Wilcock et al., 2000; Winblad et al., 2001). Several new agents are
currently under development (Aprahamian et al., 2013), two of
which have been evaluated in clinical trials: phenserine (Winblad
et al., 2010; Darreh-Shori et al., 2014) and huperzine A (Rafii
et al., 2011). Phenserine, structurally related to rivastigmine,
showed a prolonged, but mild inhibition of AChE in AD patients.
Researchers suggested an add-on therapy with donepezil to
improve the clinical efficacy of this class of agents. Low dosage of
huperzine A, a reversible AChE inhibitor, showed no significant
improvement on the ADAS-cog [the primary cognitive outcome
measure in mild to moderate AD patients (259)], in a phase
II trial in mild to moderate AD patients. Higher dosage and a
long term evaluation were suggested by the authors. A phase III
trial (CTI:NCT01282619) using sustained-release huperzine A is
currently ongoing (Ghezzi et al., 2013).
Visualization of the cholinergic system could be done by
using radiolabeled ACh analogs or inhibitors of AChE (Tavitian
et al., 1993; Irie et al., 1994; Iyo et al., 1997; Kilbourn et al.,
1996). Both pathways have been pursued by researchers, but
at present only two carbon-11 labeled compounds have been
clinically evaluated on AD patients: [11C]MP4A and [11C]MP4P,
two N-[11C]methylpiperidine esters (acetate and propionate,
Figure 2). Moreover, both compounds were used to evaluate
the effect of donepezil or rivastigmine in AD patients. Scans
FIGURE 2 | Structure of acetylcholinesterase PET tracers.
with [11C]MP4A or [11C]MP4P, taken before and after treatment
with donepezil or rivastigmine, showed significant (up to 40%)
cerebral cortical or frontal cortical inhibition of the AChE
activity. Modest symptomatic improvement was recorded for
all AD patients during these trials (Kuhl et al., 2000; Shinotoh
et al., 2001; Kaasinen et al., 2002). These studies show the
usefulness of both tracers for therapeutic monitoring of AChE
inhibitors, as well as the possibility to evaluate newly developed
drugs that target AChE (Shinotoh et al., 2004). Nonetheless,
carbon-11 labeled compounds have the limitation that an on-site
cyclotron is needed, which limits their widespread use. The
lack of significant cognitive improvement and the fact that the
cholinergic deficit is not an early event in the development of AD
(Gilmor et al., 1999), has challenged the cholinergic hypothesis
(Francis et al., 1999; Bartus, 2000; Terry and Buccafusco,
2003; Contestabile, 2011). Nevertheless, two decades after FDA
approval of tacrine, AChE inhibitors remain (out of necessity) the
mainstay for the current symptomatic treatment of AD.
Muscarinic ACh Receptor
The presynaptic cholinergic signal is transmitted through the
release of the neurotransmitter ACh, which can interact with both
muscarinic and nicotinic ACh receptors (the latter one discussed
in the next section). The pre-and postsynaptic muscarinic ACh
receptor (mAChR) is a plasmamembrane, GTP binding protein
coupled receptor, of which five subtypes exist (M1−M5) (Bonner
et al., 1987; Peralta et al., 1987; Bonner, 1989). Due to the
involvement in several neurological and psychiatric disorders,
this target has been the topic of many research papers during
the past few decades (Palacios et al., 1990; Tandon et al.,
1991; Maziere, 1995). A comprehensive autoradiography study
using tritium labeled compounds on the distribution of M1–
M4 muscarinic receptors of histopathological diagnosed AD
patients by Rodríguez-Puertas et al. (1997) showed that the
decrease of M1 muscarinic receptors followed the general pattern
of neurodegeneration as recorded in the Braak stages (Braak
and Braak, 1991), while the M2 muscarinic receptor displayed
significant reduction in the hippocampal area (up to 64%)
and a significant increase in the striatum (up to 468% in
the putamen), although this increase was not confirmed by
other research groups (Eckelman, 2002). The density of M3−4
receptors on the other hand, was not altered compared to
their density in brains of HCs. Interestingly, several research
groups demonstrated that the stimulation of the M1- and M3
muscarinic receptors lead to an increase of the neuroprotective
non-amyloidogenic pathway (formation of α-APP) (Buxbaum
et al., 1992; Nitsch et al., 1992). Stimulation of these receptors
could thus provide means for a decrease in Aβ production, a
hypothesis which was confirmed in several studies (Wolf et al.,
1995; Savonenko et al., 2005; Tsang et al., 2006). Little is known
about the M5 muscarinic receptor, the latest receptor to be cloned
(Bonner et al., 1988; Liao et al., 1989), although some research
groups have demonstrated possible involvement in regulation
of the cerebral blood flow and DA release (Yamada et al.,
2001).
A number of clinical trials have been carried out to examine
the potential role of mAChR agonists/antagonists on the clinical
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symptoms of AD patients. In the group of the selective M1
agonists, talsaclidine showed a significant decrease (up to 27%
compared to placebo) in the Aβ-CSF levels in a randomized,
double-blind, placebo controlled trial on AD patients with a
MMSE score between 12 and 26. Results should, however, be
interpreted with some caution, as suggested by the researchers,
since assessment of the amyloid burden in AD patients by
CSF has some flaws as biomarker, furthermore there was no
mention on any cognitive improvement alongside the drop in
Aβ CSF levels (Hock et al., 2000). Yet, another M1selective
agonist, cevimeline (AF102B), an FDA approved drug for the
treatment of dry mouth in Sjögren’s syndrome, did show
cognitive improvement in the ADAS-cog and word recognition
scales in a single-blind-placebo-controlled parallel group study
with patients with probable AD (Fisher et al., 1996). Dual
selectivity for both the M1- and M2-receptor on the other hand,
as it is the case for RS-86, showed no consistent cognitive
improvement in a double-blind, placebo-controlled trial on mild
to moderate AD patients (Bruno et al., 1986). Palacios et al. (1986)
hypothesized that RS-86’ failure could be due to the concomitant
stimulation of the M1- and M2 receptor, where stimulation
of M2 might inhibit the effects of the M1 receptor. On the
other hand, milameline, a partial agonist for all five muscarinic
receptor subtypes, demonstrated an effect on the rCBF in the
frontal and subcortical regions of AD patients as part of an
‘add-on study’ during a Phase III clinical trial of this drug. AD
participants were evaluated with SPECT, using the cerebral blood
flow tracer 99mTc-exametazime (99mTc-HMPAO), during the
performance of two cognitive tasks. Although a modest increase
(of 26%) of rCBF was demonstrated, the authors suggested that
there maybe neuropsychopharmacological effects associated with
the intake of milameline during the performance of cognitive
demanding tasks (Trollor et al., 2006). And finally, in a large-
scale clinical trial, xanomeline, a M1- and M4-receptor agonist
and M5 receptor antagonist (Grant and El-Fakahany, 2005),
was evaluated in a randomized, double-blind, placebo-controlled
trial on mild to moderate AD patients. Significant cognitive
improvement was hereby shown in the ADAS-cog (drug vs.
placebo; p ≤ 0.05), and the CIBIC+ scale (drug vs. placebo;
p ≤ 0.02), demonstrating that a muscarinic receptor agonist can
ameliorate cognitive symptoms in AD patients (Bodick et al.,
1997).
Only one imaging agent, with affinity for the M1- and M4
muscarinic receptor (Piggott et al., 2002), has been clinically
evaluated on AD patients thus far, namely [123I]I-quinuclidinyl
benzilate ((R,R) [123I]I-QNB) (Figure 3). Eighteen mild to
moderate AD patients and their age-matched HCs were evaluated
with [123I]I-QNB. Significantly reduced uptake (p ≤ 0.001)
was noted in the frontal rectal gyrus, right parahippocampal
gyrus, left hippocampus, and regions of the left temporal lobe,
compared to the HCs (Pakrasi et al., 2007). Nevertheless,
conflicting results have been reported by other research groups
with this tracer (Holman et al., 1985; Weinberger et al., 1991;
Wyper et al., 1993; Kemp et al., 2003), although the sample
sizes in these other studies were smaller. In another study,
[123I]I-QNB was used as a biomarker to evaluate the density
of the mAChR on 20 patients receiving the AChE inhibitor
FIGURE 3 | Structure of muscarinic PET/SPECT tracers.
donepezil (Brown et al., 2003). No distinction could be made
between donepezil responders and non-responders, furthermore
no positive correlation was found between [123I]I-QNB scans
and the extent of cognitive improvement on the ADAS-cog
scale, apart from the insular cortex, were an inverse correlation
was found. Researchers suggest that response to donepezil may
thus be greater in patients with clear cholinergic deficits. Several
efforts have been made to develop carbon-11 and fluorine-
18 labeled tracers for muscarinergic receptors (Farde et al.,
1996; Eckelman, 2001; Xie et al., 2004). A clinical trial in
the US with3-(3-(3-([18F]fluoropropyl)thio)-1,2,5-thiadiazol-4-
yl)-1,2,5,6-tetrahydro-1-methylpyridine ([18F]FP-TZTP) (Ravasi
et al., 2012; Figure 3), which binds to the M2 receptor, on
AD patients has been completed (CTI: NCT00001917), but
results are yet to be published. Lastly, recruitment for a study
with HCs and AD patients using an M4 positive allosteric
modulator [11C]MK-6884 (structure not yet available), will
soon start (CTI: NCT02621606). Future PET- and SPECT
compounds hold promise to evaluate inclusion- and outcome
criteria with novel drugs targeting the muscarinic receptor, as
well as to establish therapeutic windows via dose-occupancy
studies.
Nicotinic ACh Receptor
nAChRs are ionotropic receptors, part of the ligand-gated ion
channel superfamily (Cooper and Millar, 1997; Castelan et al.,
2008; Criado et al., 2011; Valles and Barrantes, 2012). They consist
of a hetero-or homopentameric structure, assembled from 17
possible subunits: α1−10, β1−4, γ, δ, and ε (Karlin, 2002; Gotti
and Clementi, 2004). The main subtypes of the nAChRs in the
human CNS are, however, α7, α4β2, and α3β2, although the
latter one is not involved in the pathophysiology of AD (Wevers
and Schroder, 1999; Pym et al., 2005). Reduction in nAChRs
expression levels of several subtypes has indeed been revealed
in regions with dense deposits of Aβ and NFTs (Pimlott et al.,
2004; Oddo and Laferla, 2006; Buckingham et al., 2009). The
α7 nAChR is mainly expressed in the hippocampus, whereas
the α4β2 nAChR is homogenously expressed throughout brain
(O’Brien et al., 2007; Valles and Barrantes, 2012). While loss
of α4β2 nAChR can cause memory deficits in AD patients
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(Paterson and Nordberg, 2000; O’Brien et al., 2007; Kendziorra
et al., 2011), a more complex relationship has been noted when
evaluating the interaction between α7 nAChR and Aβ in AD
(Oddo and Laferla, 2006). Aβ can either interact as agonist or
as antagonist of α7 nAChR, depending on its concentration,
where low concentrations may activate and high concentrations
may inactivate α7 nAChR (Dineley et al., 2002; Puzzo and
Arancio, 2013; Sadigh-Eteghad et al., 2014). Observations in an
AD transgenic mouse model overexpressing APP, presenilin-1,
and tau (3xTg-ADmice) (Oddo et al., 2003; Billings et al., 2005;
Kitazawa et al., 2005) were consistent with the aforementioned
in vitro conclusions for human AD, demonstrating an age
dependent reduction of α7 nAChR, as higher Aβ may eventually
block remaining α7 nAChRs (Hernandez et al., 2010). For a more
detailed discussion about the many different roles of nAChRs in
AD, readers are referred to several reviews on the subject (Oddo
and Laferla, 2006; Jurgensen and Ferreira, 2010; Vandenberghe
et al., 2010).
Since nicotine can induce the release of presynaptic ACh and
is involved in the modulation of many other neurotransmitters,
such as GABA, DA, norepinephrine, and serotonin (Levin, 1992),
several clinical studies have investigated the effect of nicotine
on AD patients (Jones et al., 1992; Wilson et al., 1995; Snaedal
et al., 1996; White and Levin, 1999). However, as mentioned
in a review by Oddo and Laferla (2006), these trails failed to
demonstrate any cognitive improvement in AD patients; only an
increase in attention could be determined. Yet, clinical trials with
two nAChR agonists did show cognitive improvement in mild
to moderate AD patients (Potter et al., 1999; Deardorff et al.,
2015). The first of them was encenicline (EVP-6124), a partial
agonist of α7 nAChR. This drug was well tolerated in Phase I
and II trials, showing significant improvement in cognitive and
functional domains (Deardorff et al., 2015). A currently ongoing
Phase III trial involving mild to moderate AD patients, receiving
or having already received AChE inhibitors, to assess the efficacy
and tolerability of EVP-6124 (ECT: 2012-003209-92) in a large
group of patients was halted due to severe gastrointestinal side-
effects (Shugart, 2016). Another nAChR agonist, ABT-418, which
has binding affinity for α4β2, α2β2, and α3β4 (Potter et al.,
1999), showed some cognitive improvement in the acquisition
and retention of verbal information of patients with early AD
(Mean MMSE score of 21.4). It is, however, unclear whether this
compound will be further pursued in large clinical trials. Two
other trials with nAChR agonists were less convincing; efficacy of
ispronicline (TC-1734 or AZD-3480) a selective agonist of α4β2
nAChR and α2β2 nAChR (Gatto et al., 2004) was investigated
in a large Phase IIb dose-finding study on mild to moderate AD
patients (MMSE score: 12–26). Despite the fact that ispronicline
caused significant improvement on patients with age-associated
memory impairment (Dunbar et al., 2007, 2011), no significant
improvement could be shown on the ADAS-cog scale in the latest
Phase IIb study, although secondary outcome measurements did
show some improvement (Frolich et al., 2011). Additional Phase
II trials on mild to moderate AD patients were halted, since no
superiority over donepezil could be demonstrated. Finally, in a
Phase II trial on mild to moderate AD patients (MMSE score of
26–26 and 14–20, respectively), no cognitive improvement could
be observed with the α4β2 nAChR selective agonist varenicline
(Kim et al., 2014). Researchers concluded that the dosing regimen
was not optimal and overall longer (than 6 weeks) trials may
be needed to show cognitive improvement. In the light of these
two failed clinical trials with α4β2 nAChR agonists, another
clarification could, however, be that the α4β2 nAChR subtype
may only play a minor role on cognitive processes in AD,
and α7 nAChR is therefore a more suitable target (Kim et al.,
2014).
While nicotine was not really used as a therapeutic drug, as
a carbon-11 labeled PET tracer it successfully showed reduction
of nAChR in AD patients reflecting the loss of the nicotinic
receptors during disease progression, in comparison with control
subjects (Nordberg et al., 1990; Nordberg et al., 1995; Kadir
et al., 2006). Additionally, a number of other clinical studies
used [11C]nicotine PET imaging (Figure 4), to assess the efficacy
of the AChEIs tacrine and rivastigmine (Nordberg et al., 1992;
Nordberg et al., 1997; Nordberg et al., 1998; Kadir et al., 2007).
Significant increase in nAChR expression compared to baseline
in several cortical areas could be demonstrated, after treatment
with both tacrine and rivastigmine. [11C]nicotine does, however,
show high non-specific binding and rapid brain wash-out,
making quantitative PET assessments of nAChR difficult. A few
other PET radiotracers are currently under development for
imaging of α7 and α4β2 nicotinic receptors (Toyohara et al., 2010;
Meyer et al., 2014; Chalon et al., 2015); two structurally related
compounds, one SPECT and one PET tracer, with affinity for
the α4β2 nicotinic receptor have already been evaluated on AD
patients (O’Brien et al., 2007; Ellis et al., 2008; Sabri et al., 2008).
Reduced tracer uptake was noted in AD patients in the frontal
lobe, striatum, right medial temporal lobe and the pons after
scans with-5-[123I] iodo-3-[2(S)-2-azetidinylmethoxy]pyridine
([123I]5IA-85350) (Figure 4), consistent with known reductions
of the α4β2 nicotinic receptor in AD (O’Brien et al., 2007). Its PET
counterpart, 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine
(2-[18F]FA-85380) (Figure 4), was able to demonstrate significant
reduction (up to 75%) of the α4β2 nicotinic receptor in MCI
patients, which later on converted to AD (Sabri et al., 2008). In
another study with 2-[18F]FA-85380, the possible relationship
between Aβ depositions and the reduction of the α4β2 nicotinic
receptor was studied by evaluating early to moderate AD patients
(Okada et al., 2013). A negative correlation between the presence
of Aβ in the medial frontal cortex and the nucleus basalis
magnocellularis, as assessed by [11C]Pittsburgh Compound B
([11C]PiB, an Aβ tracer), and the binding of 2-[18F]FA-85380
to the α4β2 nicotinic receptor could be established. Both α4β2
nicotinic receptor tracers suffer, however, from slow kinetics,
FIGURE 4 | Structure of nicotinic PET/SPECT tracers.
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leading to long scanning times, making routine application
difficult (Meyer et al., 2014). Conversely, a novel α4β2 nAChR
tracer, 2-{5-[2-[18F]fluoropyridin-4-yl]pyridin-3-yl}-7-methyl-
7-azabicyclo[2.2.1]heptane ([18F]XTRA) (Meyer et al., 2014)
(Figure 4), showed much faster pharmacokinetics, which allow
scanning within a reasonable time frame. Recruitment for a
clinical trial with [18F]XTRA on HCs, an AD or a MCI patient is
currently ongoing (CTI:NCT01894646).
TAU HYPOTHESIS
As one of the pathological hallmarks in well over 20
neurodegenerative diseases (Lee et al., 2001), tau (tubulin
associated unit), gained an increasing interest in the past few
years, partly as a result of the large failure rate of clinical trials
targeted toward the amyloid hypothesis (Barthel et al., 2015), but
also due to recent availability of several tau specific PET ligands
(Villemagne et al., 2015). As a member of the microtubule-
associated protein (MAP) family, tau is mainly localized in
the distal part of the neuronal axons (Binder et al., 1986).
Consequently, the primary function of tau is stabilization and
support of the microtubules (Weingarten et al., 1975). There are
six different isoforms of tau, depending on alternative splicing of
exon two, three, and ten of the MAPT. Localized on chromosome
17q32, this gene contains 16 exons (Neve et al., 1986). Exon
two and three both encode a 29-aminoacid fragment at the
N-terminal part of tau, yielding isoforms with none (0N), one
(1N), or two inserts (2N). Exon ten on the other hand, encodes
a 31-aminoacid fragment, which results in either three (3R) or
four (4R) repeated binding domains at the C-terminus of the
protein. The mature human brain contains thus six isoforms of
tau: 0N3R, 1N3R, 2N3R, 0N4R, 1N4R, and 2N4R. Under normal
conditions (and in AD) there is a 1:1 ratio of the 3R- and 4R
isoforms, but this ratio somehow shifts in certain pathological
conditions (Hong et al., 1998). The exact physiological role of
these various isoforms remains to be elucidated, although 4R
isoforms are better at promoting microtubuli assembly, and have
greater binding affinity for microtubuli than the 3R isoforms
(Goedert and Jakes, 1990; Butner and Kirschner, 1991). Under
non-pathologic conditions, tau is a highly soluble protein with
a limited secondary structure (Dunker et al., 2008), prone to
several post-translational modifications. The most important
one is phosphorylation on its serine and threonine residues,
which modulates microtubule binding (Martin et al., 2011). Then
again, in pathological conditions, such as AD, tau will become
hyperphosphorylated, detaches from the microtubules and will
self-aggregate into insoluble PHFs and NFTs, compromising
neuronal cell function (Iqbal and Grundke-Iqbal, 2008). Different
shapes and sizes of the aggregates can be found under diverse
cognitive conditions, related to the presence of various isoforms,
and post-translational modifications (Ballatore et al., 2007). In
AD, the spreading of the tau pathology, which is thought to
proceed in a prion-like manner (de Calignon et al., 2012),
has been well-documented in the different Braak stages (Braak
and Braak, 1991). Furthermore, several studies confirmed that
this characteristic pattern of aggregated tau spread closely
correlates to the clinical symptoms of AD, as measured by the
MMSE (Bancher et al., 1993, 1996; Duyckaerts et al., 1997;
Grober et al., 1999). This makes tau an interesting target for
drug development. Due to the complexity of aggregated tau
as a drug target, several tau-associated approaches have been
investigated.
Glycogen synthase kinase 3β, being the dominant isoform
of three GSK-3 variants (Jaworski et al., 2011), is the main
kinase responsible for the hyperphosphorylation of tau, and
hence an important potential target for disease-modification
(Maqbool et al., 2016). Diverse GSK-3 inhibitors were reported
the last few years by many research groups (Noble et al.,
2011; Berg et al., 2012; Maqbool et al., 2016). Lithium and
valproate were the first compounds to be clinically evaluated,
but due to inconsistent and overall disappointing results, they
were largely discontinued (Noble et al., 2005; Hampel et al.,
2009; Tariot and Aisen, 2009; Tariot et al., 2011). Several other
GSK-3 inhibitors have, however, been pursued (Maqbool et al.,
2016), two of which, tideglusib (NP0311212) and AZD1080,
entered clinical trials (King et al., 2014; Lovestone et al., 2015).
Development of AZD1080 was, however, halted in Phase I due to
nephrotoxicity problems (Eldar-Finkelman and Martinez, 2011)
and no clinical benefit was seen with tidelusib on patients with
mild to moderate AD in Phase II clinical trials. Dose finding
studies and longer trials are now required with the latter drug
to examine its possible long term benefit (Lovestone et al.,
2015). Another tau-associated approach is the inhibition of tau-
aggregation (Bulic et al., 2009, 2010). The first of this class to
be pushed in Phase II clinical trials, methylthioninium chloride
(methylene blue, MTC), a phenothiazine derivative, was able
to stabilize disease progression over a period of 50 weeks in
mild and moderate AD patients (Wischik et al., 2015). The
brain bioavailability of this charged drug remains, however, to
be elucidated. The pro-drug of MTC, leuco-methylthioninium
(TRx0237 or LMTX), with a superior pharmacological profile
(Wischik et al., 2014) will now be evaluated in three parallel Phase
III trials on mild to moderate AD patients and patients with
FTD (CTI: NCT01689246, NCT01689233, and NCT01626378).
And finally, an increasing interest toward tau immunotherapy
has been noted, as means of removing tau aggregation by the
patients’ own immune system (Asuni et al., 2007). Two drugs of
this kind, ACI-35 (ECT: 2015-000630-30) and AADvac1 (CTI:
NCT02031198) are currently being evaluated in Phase I and II
trials.
Despite the historical importance of tau as a pathological
hallmark in AD (Graeber and Mehraein, 1999), only recently
tau specific PET ligands have been developed. One of major
issues during tau PET development is the lack of a representative
tau-animal model, which may be explained by (ultra)structural
differences between murine and humane tau (Duyckaerts
et al., 2008). More than a few tracers are, however, currently
being clinically evaluated. The first tau PET ligand to be
reported was 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-
naphthyl}ethylidene)malononitrile ([18F]FDDNP) (Figure 5),
although not specific for tau as such, high binding affinity was
reported in several neurodegenerative diseases (Bresjanac et al.,
2003; Small et al., 2006; Kepe et al., 2010; Nelson et al., 2011;
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FIGURE 5 | Structure of tau PET tracers.
Kepe et al., 2013; Small et al., 2013). Limited dynamic range of
signal and relatively low affinity for tau, led to the development
of novel tau directed ligands with similar structural moieties.
Yet, the first real approach toward tau specific ligands was
achieved by researchers of the Tohoku University in Japan with
the development of 4-{6-[2-[18F]fluoroethoxy]quinolin-2-yl}
aniline ([18F]THK523) (Fodero-Tavoletti et al., 2011) (Figure 5).
While [18F]THK523 was able to visualize the known pattern
of tau distribution in AD patients, high white matter binding
and unfavorable pharmacokinetics (Villemagne et al., 2014)
led to the development of three novel 2-arylquinoline
derivatives: 1-({2-[4-(dimethylamino)phenyl]quinolin-6-yl}oxy)
-3-[18F]fluoropropan-2-ol ([18F]THK5105) (Okamura et al.,
2014a), 1-[18F]fluoro-3-({2-[4-(methylamino)phenyl]quinolin-
6-yl}oxy)propan-2-ol ([18F]THK5117) (Ishiki et al., 2015) and
the optically pure (2S)-1-[18F]fluoro-3-({2-[4-(methylamino)
phenyl]quinolin-6-yl}oxy)propan-2-ol ([18F]THK5351) (Harada
et al., 2016) (Figure 5). All three compounds showed high
binding in AD patients, with radiotracer retention in sites
known for their tau deposition. Of these three compounds,
[18F]THK5351 showed superior pharmacokinetics, highest
signal-to-noise ratio and the lowest white matter binding
(Okamura et al., 2014b; Harada et al., 2016). Further clinical
trials in Japan with [18F]THK5351 are underway (UMIN-CTR:
UMIN000013929 and UMIN000018496). Often considered by
many research groups as the current benchmark in tau PET
development, 11-{4-[2-[18F]fluoroethyl]piperidin-1-yl}-1,8,10-
triazatricyclo[7.4.0.02,7]trideca-2(7),3,5,8,10,12-hexaene ([18F]
T808 or [18F]AV680), and 2-[18F]fluoro-5-{5H-pyrido[4,3-
b]indol-7-yl}pyridine ([18F]T807 or [18F]AV1451) (Figure 5)
have high affinity and selectivity for tau over Aβ (Zhang
et al., 2012; Xia et al., 2013; Shah and Catafau, 2014). A small
first-in-man study with [18F]T808 in eight AD patients (mean
MMSE of 18) and their three age matched HCs, showed a
rapid brain uptake and washout in HCs, and a tau pattern
consistent with the Braak stages in the AD group (Chien
et al., 2013). Interestingly, one of the AD patients who died
a few weeks after his PET scan with [18F]T808, showed close
correlation with his histopathological staining (Dani et al.,
2015). Nonetheless, substantial bone uptake was observed
with this compound (Villemagne et al., 2015), which led to
the development of [18F]T807. In comparison to [18F]T808,
[18F]T807 has slower kinetics and a relatively lower affinity
for tau, but [18F]T807 does not show defluorination (Xia
et al., 2013). Similar clinical findings as with [18F]T808 were
demonstrated with [18F]T807 in a small first-in-man study on
three HCs, in one patient with MCI (MMSE score of 26) and
one severe AD patient (MMSE score of 7) in comparison with
three HCs. Remarkably, the tracer retention was significantly
lower in the patient with MCI, as compared to the patient
with severe AD (Chien et al., 2012). A series of large clinical
trials (ClinicalTrial.gov and EU Clinical Trials Register: search
term: ‘T807’ OR ‘AV1451’ AND ‘PET’) is underway with
[18F]T807 to evaluate its applicability not only in AD, but
also in several other tauopathies. Being thus far the only
compound to be able to visualize tau (and possibly different
isoforms) in AD, but also in PSP and CBD (Maruyama et al.,
2013), 2-((1E, 3E)-4-(6-([11C]methylamino)pyridin-3-yl)buta-
1,3-dienyl)benzo[d]thiazol-6-ol ([11C]PBB3) received a lot of
interest (Figure 5). Clinical studies on AD patients and a CBD
patient, as compared to HCs, showed increased tracer uptake,
consistent with the Braak stages (for the AD case), and higher
retention in the basal ganglia (for the CBD case). Stability
issues and a challenging radiosynthesis might, however, limit
its commercial use. Several other tau directed PET ligands
from Roche, such as [11C]RO6931643, [11C]RO6924963, and
[18F]RO6958948 (structures not available) have been evaluated
in a Phase I clinical trial, but data are yet to be published (CTI:
NCT02187627) (Dani et al., 2015). Other clinical studies with
[18F]MK-6240, [18F]MNI-798, and [18F]MNI-815 (structures
not available) on AD cases are currently recruiting patients
(CTI: NCT02562989, NCT02640092, and NCT02531360). For
a more detailed discussion about the current state of tau PET
development, readers are referred to some excellent reviews
on the subject (Okamura et al., 2014b; Zimmer et al., 2014;
Dani et al., 2015). An important question that remains to be
elucidated is for which isoforms these tau PET tracers have
affinity; a question which may have major implications on
the differential diagnosis of closely related neurodegenerative
tauopathies. Nevertheless, the substantial progress that has
been made in this field will make it possible to allow in vivo
detection of tau in AD and thus the reassessment of inclusion-
and outcome criteria of clinical trials aiming to intervene at
tau-aggregates.
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AMYLOID HYPOTHESIS
For many decades, the amyloid hypothesis has been the main
pathological model of AD (Hardy and Higgins, 1992; Korczyn,
2008), accepted by most researchers, and only recently contested
(Hardy, 2006). It postulates that extensive deposits of amyloid
in the human brain are the central lesions in the development
of AD, responsible for a neurotoxic cascade of events, which
ultimately leads to dementia (Barage and Sonawane, 2015). Aβ
peptides, the main component of SP (Gomez-Isla et al., 1997),
are 39–43 amino acid residues, formed during the sequential
cleavage of the transmembrane APP by β-secretase 1 (also called
BACE1) (Haass, 2004), followed by the action of the γ-secretase
(Selkoe, 2001). Under ‘normal’ conditions APP is cleaved in a
non-amyloidogenic pathway by the action of initially α-secretase,
forming α-sAPP, which may have a neuroprotective function
(Pagani and Eckert, 2011). α-sAPP is then further cleaved by
γ-secretase to eventually produce P3. The function of APP itself
is unknown, although a possible role in the Cu-homeostasis
has been proposed (Barnham et al., 2004). There are two main
isoforms of Aβ: Aβ40 and Aβ42, the latter one being more prone to
aggregation and regarded as the main neurotoxic species (Ballard
et al., 2011). Once formed, Aβ species will undergo several
characteristic changes, from small oligomers into larger fibrils,
which eventually form diffuse and later neuritic plaques. These
plaques frequently trigger astrocytosis, activation of microglial
cells, cytokine release, and a multi-protein neuroinflammatory
response (Barage and Sonawane, 2015). Just like the NFTs,
amyloid depositions follow a specific pattern, as recorded by
Braak and Braak (1991). In contrast to the NFTs, however,
there is a poor correlation between the extent of these plaques
and the degree of cognitive impairment (Nelson et al., 2012),
furthermore non-demented individuals can heave substantial
loads of Aβ deposition without revealing any clinical symptoms
(Villemagne et al., 2008). Recently, several studies pointed toward
Aβ oligomers, and not amyloid plaques, as the main toxic
species in AD (Haass and Selkoe, 2007; Minati et al., 2009).
For a more extensive discussion about the neuropathological
role Aβ plays in AD, readers are referred to other reviews
(Haass and Selkoe, 2007; Hardy, 2009; Barage and Sonawane,
2015).
Huge efforts have been undertaken to develop disease altering
drugs that target the amyloid deposition, but unfortunately many
failed during clinical trials (Barthel et al., 2015). Some of the
most recent ongoing trials targeting the amyloid deposits are
summarized in Table 1. Various therapeutic approaches are to be
considered when targeting Aβ (Barage and Sonawane, 2015). We
will discuss here the most important tactics, together with some
of their constraints, as it is imperative to know why so many trials
fail in this area. One of many methods applied, is the reduction
of Aβ production through inhibition of β-and/or γ-secretase
or activation of α-secretase (Cummings, 2008). Indeed, the
therapeutic potential of BACE1 inhibitors has been demonstrated
in BACE1 knockout mice, which produced significantly (15-fold)
less Aβ (Luo et al., 2001; Roberds et al., 2001). Nonetheless,
inhibition of BACE1 causes several problems, since BACE1 has
been shown to have many physiological roles, which might lead
to toxicity problems when using BACE1 inhibitors. Furthermore,
BACE1 inhibitors need to be quite bulky, due to the relatively
large active site and this can cause BBB passage issues (Ghezzi
et al., 2013). Inhibition of the multimeric γ-secretase complex
encounters similar problems as the use of BACE1 inhibitors,
TABLE 1 | Ongoing clinical trials with drugs targeting the amyloid hypothesis (Han and Mook-Jung, 2014; Wischik et al., 2014; Apter et al., 2015).
Drug Approach Trial phase CTI PET biomarker∗ EudraCT number
MK-8931 BACE1 inhibitor 3 NCT01953601 [18F]flutemetamol 2012-005542-38
2/3 NCT01739348 [18F]flutemetamol 2011-003151-20
AZD3293 BACE1 inhibitor 2/3 NCT02245737 [18F]AV-45 / [18F]FDG 2014-002601-38
PF-03084014 γ-secretase inhibitor 2 NCT01981551 Not specified /
NIC5-15 γ-secretase inhibitor 2 NCT01928420 Not specified /
Bryostatin-1 α-secretase enhancer 2 NCT00606164 Not specified /
2 NCT02431468 Not specified /
Solanezumab Passive immunization 2/3 NCT01760005 [11C]PiB / [18F]FDG 2013-000307-17
3 NCT01900665 [18F]AV-45 2013-001119-54
Gantenerumab Passive immunization 3 NCT02051608 [18F]AV-45 2013-003390-95
3 NCT01224106 Not specified 2010-019895-66
2/3 NCT01760005 [11C]PiB / [18F]FDG 2013-000307-17
Crenezumab Passive immunization 1 NCT02353598 [18F]AV-45 /
2 NCT01998841 Not specified /
2 NCT01723826C Not specified 2012-003242-33
BAN2401 Passive immunization 2 NCT01767311 Not specified 2012-002843-11
Gammagard Passive immunization 2/3 NCT01561053 [18F]FDG /
Aducanumab Passive immunization 3 NCT02484547 Not specified 2015-000967-15
3 NCT02477800 Not specified 2015-000966-72
1 NCT02434718 Not specified /
∗C = Completed; PET biomarkers are either used as inclusion criteria and/or as outcome measure.
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as γ-secretase has many other physiological roles as well,
especially cleavage of the Notch receptor, necessary for growth
and development (Yiannopoulou and Papageorgiou, 2013). Brain
penetration seems to be an issue as well in this area (Imbimbo
and Giardina, 2011). Increasing the α-secretase activity, and thus
promoting the non-amyloidogenic pathway, is another way to
reduce the Aβ load. Less is however known about the possible
physiological consequences of such an upregulation (Barage and
Sonawane, 2015). Another way of interfering with the Aβ load
is by modulation of Aβ aggregation, as increasing evidence
suggests that soluble oligomers, which act as intermediates for
the formation of aggregates, are the most toxic species in AD
disease (Dahlgren et al., 2002; Hoshi et al., 2003; Kayed et al.,
2003). Yet, the most promising small molecules ultimately failed
due to their (toxic) pharmacological profile (Santa-Maria et al.,
2007; Rishton, 2008; Yiannopoulou and Papageorgiou, 2013).
Several studies also showed the relationship of APP and Aβ with
mitochondrial dysfunction in AD (Anandatheerthavarada et al.,
2003; Lustbader et al., 2004; Caspersen et al., 2005); interaction
of both proteins with mitochondrial matrix proteins, such as
Aβ-binding alcohol dehydrogenase and adenosine triphosphate
synthase subunit alpha, could directly lead to mitochondrial
toxicity, and thus oxidative stress (Devi et al., 2006; Reddy and
Beal, 2008). Numerous antioxidant agents have been described
and evaluated in clinical trials with MCI- and AD patients, and
several studies are still ongoing (Mecocci and Polidori, 2012;
Polidori and Nelles, 2014). Conflicting results were, however,
reported and overall small cognitive benefit was seen during
these trials. Long-term trails are now warranted in order to
establish clinical benefits in AD. Then again, several promising
antioxidative compounds are currently being investigated (Qosa
et al., 2015; Rigacci, 2015). Still, the primary action in targeting
amyloid came from monoclonal antibodies. First discovered by
Schenk et al. (1999) to be very effective in reducing the Aβ load
in mice, the mechanism of action of amyloid immunotherapy
remains, however, to be fully elucidated (Yiannopoulou and
Papageorgiou, 2013). Nevertheless, only a small fraction (0.1% of
the injected dose) of antibodies seems to be able to pass the BBB
in humans (Banks et al., 2002). A higher fraction of antibodies
in the brain may thus be needed to be therapeutically effective.
This hurdle was the topic of two recently reported reviews
(Lemere, 2013; Spencer and Masliah, 2014). Despite the low
BBB’s passage, one of the major concerns with immunotherapy is
the development of serious side effects, for instance encephalitis
(active immunization), microhemorrhages, or vasogenic edemas
(passive immunization) (Orgogozo et al., 2003; Panza et al.,
2012). Another important factor to consider is the time of
intervention in the AD state; immunotherapy is probably most
efficacious in early disease states, when there is more function
to preserve (Barthel et al., 2015). Efficient biomarkers, that
can predict the conversion from MCI to AD, are therefore of
utter importance. Using longitudinal PET biomarkers to assess
and follow up the amyloid burden in clinical trials would
indeed allow a more confident formulation of inclusion, but
also outcome criteria (Barthel et al., 2015). Several amyloid
PET tracers are currently being used for these purposes (see
Table 1).
Although not FDA-approved, 2-{4-[[11C]methylamino]
phenyl}-1,3-benzothiazol-6-ol ([11C]PiB) (Figure 6) has been
used for many years as benchmark compound for in vivo
imaging of the amyloid load in AD patients (Benadiba et al.,
2012). Results of those trials have shown that clinically diagnosed
AD cases have positive amyloid scans (Kemppainen et al., 2006;
Jack et al., 2008, 2009; Lowe et al., 2009), and the ones that did
not have positive scans, were most likely to be misdiagnosed
(Rabinovici et al., 2007; Rabinovici et al., 2008). Furthermore,
increased [11C]PiB binding is able to predict the conversion
of MCI to AD (Okello et al., 2009). [11C]PiB has also been
proven useful in the differential diagnosis of FTD and AD, as
FTD patients typically have a normal [11C]PiB uptake (Rowe
et al., 2007; Engler et al., 2008). Interestingly, a close correlation
has been noted with CSF Aβ levels (Tolboom et al., 2009;
Weigand et al., 2011), firmly establishing [11C]PiB as an Aβ
biomarker. There are, however, a few limitations with [11C]PiB
as an amyloid biomarker; [11C]PiB presumably binds to diffuse
plaques and not to the more cognitive correlated neuritic plaques
(Jack et al., 2013). Moreover, commercial use is excluded, due
to the short half-life of carbon-11. Several attempts were thus
undertaken to develop 18F-labeled analogs (Koo and Byun,
2013). Three of them: 4-[(E)-2-[6-(2-{2-[2-[18F]fluoroethoxy]
ethoxy}ethoxy)pyridin-3-yl]ethenyl]-N-methylaniline ([18F]flor-
betapir or [18F]AV-45), 2-[3-[18F]fluoro-4-(methylamino)
phenyl]-1,3-benzothiazol-6-ol ([18F]flutemetamol, [18F]GE-
067 or [18F]AV-1) and 4-[(E)-2-[4-(2-{2-[2-[18F]fluoroethoxy]
ethoxy}ethoxy)phenyl]ethenyl]-N-methylaniline([18F]florbeta-
ben or [18F]BAY 97-9172) (Figure 6) have already been approved
by the FDA and the EMA for their binding to neuritic plaques.
Another one, 2-[2-[18F]fluoro-6-(methylamino)pyridin-3-yl]-1-
benzofuran-6-ol ([18F]AZD-4694 or [18F]NAV4694) (Figure 6),
is currently awaiting FDA-approval (Jack et al., 2013). Although
all of the current 18F-labeled compounds show significant
increased uptake in AD patients as compared to HCs in clinical
FIGURE 6 | Structure of Aβ PET tracers.
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trials (Rowe et al., 2008, 2013; Barthel et al., 2011; Villemagne
et al., 2011), they suffer from high non-specific white matter
binding, as compared to [11C]PiB (Benadiba et al., 2012;
Rowe and Villemagne, 2013; Vandenberghe et al., 2013). Only
[18F]AZD-4694 has a white matter uptake similar to [11C]PiB
(Rowe et al., 2013). While a negative amyloid PET scan will
exclude AD, a positive scan, on its own, is insuffient for the
diagnosis of AD, as has been shown with [18F]florbetapir in
clinic (Yang et al., 2012). Furthermore, limited reimbursement of
these recently approved compounds limits their use in clinical
practice (Barthel et al., 2015). The use of amyloid PET may,
however, reveal true AD cases. Moreover, the amyloid tracers
are able to predict the conversion from MCI to AD, and this can
considerably influence decision making in AD related clinical
trials (Rowe and Villemagne, 2013).
GAMMA-AMINOBUTYRIC ACID
RECEPTORS
The inhibitory GABA system in the CNS consists of three GABA
receptor systems: GABAA, GABAB and GABAC (Chebib and
Johnston, 1999). Since GABAB- and GABAC receptors have
not been clinically evaluated in AD yet, focus will be toward
the GABAA receptor. The GABAA receptor is a pentameric
ligand gated ion channel, composed of a wide array of (possible)
subunits: α1−6, β1−3, γ1−3, δ, ε, τ,pi, and ρ1−3 (Mehta and Ticku,
1999). In order to be functional, the receptor seems to require
the presence of at least one α- and one β-subunit. The most
common composition is a pentamer composed of two α-, two β-
, and one γ-subunit (Connolly et al., 1996). The GABA system
plays an important role in AD, as it is one of the main culprits
for the BPSD. Contributing to these BPSD, the GABA system
is also known to modulate other neurotransmitters, such as
serotonin, DA and ACh (Decker and McGaugh, 1991; Zorumski
and Isenberg, 1991; Keverne, 1999). It has been a long standing,
although contested (Lanctot et al., 2004), view that the GABA
system undergoes little change during AD progression, due to
dynamic plasticity of the system (Rissman et al., 2007). Recent
findings suggest, however, otherwise and point to a severely
altered GABAergic signaling in AD, with possible modulation
of tau hyperphosphorylation (Lanctot et al., 2004; Limon et al.,
2012; Nykanen et al., 2012). A more detailed discussion of
the GABAsystem and its putative role in AD can be found in
some extensive reviews (Marczynski, 1998; Lanctot et al., 2004;
Rissman et al., 2007).
Benzodiazepines, which are allosteric modulators of the
GABAA receptor (Hevers and Luddens, 1998), have long been
used for the symptomatic treatment of anxiety and agitation in
AD (Kirven and Montero, 1973; Covington, 1975; Sunderland
et al., 1989; Zec and Burkett, 2008), nevertheless there is a need
for randomized controlled trials to evaluate the true efficacy
of these drugs in AD (Defrancesco et al., 2015). Caution is
also to be advised with BZDs, as there are reports of rapid
cognitive and functional decline in AD patients when taking
these drugs for an extensive period of time (Zec and Burkett,
2008).
FIGURE 7 | Structure of GABAergic PET/SPECT tracers.
There have been numerous endeavors to developed
radiotracers for in vivo imaging of the GABAA receptors
(Katsifis and Kassiou, 2004; Andersson and Halldin, 2013). Ethyl
12-fluoro-8-[11C]methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.022,6]
tetradeca-1,3,5,10,12-pentaene-5-carboxylate ([11C]flumazenil)
(Figure 7), a GABAAantagonist with affinity for the α1−3
and α5-subunit, is the most promising tracer thus far. Several
clinical studies have been performed with [11C]flumazenil
(Savic et al., 1988; Heiss et al., 2004; Frankle et al., 2009,
2012; Andersson and Halldin, 2013), one of which was carried
out on early AD patients (Mean MMSE: 21.2) to evaluate
the GABAA receptor density. Researches demonstrated a
marked decrease in [11C]flumazenil binding, which correlated
well with neuronal loss as evaluated by histopathological
findings (Brun and Englund, 1981; Andersson and Halldin,
2013). The SPECT analog ethyl 11-[123I]iodo-8-methyl-9-oxo-
2,4,8-triazatricyclo[8.4.0.02,6]tetradeca-1,3,5,10,12-pentaene-5-
carboxylate ([123I]iomazenil) (Figure 7), showed significantly
reduced uptake in the temporal, parietal end occipital cortex
of moderate to severe AD patients (Soricelli et al., 1996;
Fukuchi et al., 1997). In contrast to [11C]flumazenil though,
[123I]iomazenil was not able to show significant changes in
early AD patients (Pappata et al., 2010). Interestingly, in a
direct PET-SPECT comparison study on healthy volunteers
between [11C]flumazenil and [123I]iomazenil, the 123I-labeled
variant came out as the better candidate, due to a better fit in
compartmental modeling with SPECT (Bremner et al., 1999).
These radiopharmaceuticals not only hold promise to be used
as inclusion- and outcome criteria for drugs combatting BPSD
symptoms in AD, but they could also be used in dose-occupancy
studies to assess the (sometimes small) therapeutic window of
BZDs.
SEROTONERGIC SYSTEM
Serotonin (5-HT), is a neurotransmitter that plays a complex
role in the modulation of several psychological, emotional, and
cognitive processes. Moreover, 5-HT affects long-term and short-
term memory and cognitive function through the regulating of
many other neurotransmitters, such as ACh, DA, GABA, and
glutamate (Rodríguez et al., 2012). The principal 5-HT-source
in the human brain comes from neurons in the raphe nuclei,
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with various projections throughout the CNS (Vertes, 1991;
Vertes et al., 1999). There are seven main 5-HTRs, which can be
divided into two major classes: the G-protein coupled receptors
(5-HTR1,2,4−7) and the ligand-gated cation channels (5-HTR3),
many of which have also several subcategories (Hoyer et al.,
2002). For the ‘normal’ physiological and pharmacological role
of these receptors, readers are referred to several reviews on the
topic (Barnes and Sharp, 1999; Hoyer et al., 2002; Niesler et al.,
2008). An overall reduction of the serotonergic system in AD
pathology, likely reflecting the loss of serotonergic projections
from the raphe nuclei, has been demonstrated (Bowen et al.,
1983; Chen et al., 1996, 2000). Interestingly, loss of function
seems more extensive in early onset AD than in later-onset AD,
which may be due to compensating systems (Arai et al., 1992;
Halliday et al., 1992). More specifically, marked reduction of the
5-HTR1A, which is expressed in brain areas known for their role
in memory and learning, has been noted in the hippocampus and
the frontal cortex during AD progression (Lai et al., 2003). This
may, however, reflect a compensatory mechanism for reduction
of cholinergic receptors in the AD brain, since inhibition of the
5-HTR1A has been implicated in the release of ACh (Millan
et al., 2004; Kehr et al., 2010; Rodríguez et al., 2012). Another
receptor that is affected during AD progression is 5-HTR2A,
with reductions being noted in the frontal, temporal, parietal
and enthorinal cortex and the hippocampus (Crow et al., 1984;
Procter et al., 1988; Dewar et al., 1990). In a review by Rodríguez
et al. (2012) it was suggested that a decrease in 5-HTR2A may
effect cognitive functions in AD patients. A positive correlation
between cognitive decline and 5-HTR2A related decrease in the
frontal cortex has indeed been noted (Lai et al., 2005). Moreover,
it was implied that decrease in 5-HTR2A density may be due to
pathological accumulation of Aβ (Christensen et al., 2008; Holm
et al., 2010). Stimulation of the 5-HTR4 may lead to an increase
of the non-amyloidogenic pathway in vitro (Consolo et al., 1994;
Robert and Benoit, 2008), indication for an important role in APP
metabolism. Other 5-HTRs with marked reduction in AD are 5-
HTR1B, 5-HTR1D, and 5-HTR6 (Garcia-Alloza et al., 2004; Lorke
et al., 2006). Additionally, reduction of the former two correlates
well with the cognitive decline in AD (Garcia-Alloza et al.,
2004). Significant decrease (up to 25%) in binding sites of the 5-
HTT during AD progression is also to be noted (Bowen et al.,
1983; Ouchi et al., 2009). As part of the monoamine transporter
family, the SERT is responsible for removal of serotonin from the
synaptic cleft. There seems, however, no correlation between the
reduced density of this transporter and BPSD symptoms, as seen
in AD (Tsang et al., 2010).
Most drugs targeting the serotonergic system are used as
adjuvant therapy, combatting BPSD symptoms by inhibition
of SERT and/or the norepinephrine transporter. Recent meta-
analyses have proven their efficacy in treating these behavioral
symptoms in AD (Ballard and Corbett, 2010; Henry et al.,
2011). Some serotonin reuptake inhibitors have, however, also
been evaluated for their possible cognitive enhancement in AD
patients (See Table 2). Likewise, increasing interest has been
noted for 5-HTR drugs that are able to improve cognition
and/or memory in AD. 5-HT1-, 5-HT4-, and 5-HT6 receptors
are hereby of particular interest, due to their important role in
learning and memory processes (Geldenhuys and Van der Schyf,
2011), effects which are most likely due to their modulation on
glutamatergic and cholinergic transmission, or, in the case of 5-
HT-4, due to an enhanced release of ACh upon stimulation of this
receptor (Rodríguez et al., 2012). An overview of trials that have
looked into the clinical benefit of serotonergic drugs on cognitive
impairment in AD patients is given in Table 2.
Although much progress has been made in the development
of PET- and SPECT radioligands for visualization of the
serotonergic system (Paterson et al., 2013), only a few
radiolabeled compounds have been evaluated on AD patients
TABLE 2 | Enhancement of cognitive functions in AD by drugs that modulate serotonergic neurotransmission (Geldenhuys and Van der Schyf, 2011;
Ramirez et al., 2014).
Drug Mechanism Trial (Phase) Outcome Reference/ongoing trail
Lecozotan (SRR-333) 5-HTR1A antagonist 2 Unsuccessful due to adverse effects Sabbagh, 2009
Xailiproden (SRR57746A) 5-HTR1A antagonist 3 Unsuccessful to demonstrate efficacy Sabbagh, 2009
PRX-03140 5-HTR4 agonist 2 Improvement on ADAS-cog scale Sabbagh, 2009
SB-742457 5-HTR6 antagonist 2 Improvement on CIBIC+ score and ADAS-cog scale Maher-Edwards et al., 2010
Lu-AE-58054 (SGS-518) 5-HTR6 antagonist 2 Improvement on ADAS-cog scale and ADL Rodríguez et al., 2012
3 Ongoing NCT02079246
3 Ongoing NCT02006654
3 Ongoing NCT02006641
3 Ongoing NCT01955161
PF-05212377 (SAM-760) 5-HTR6 antagonist 2 Ongoing Rodríguez et al., 2012/NCT01712074
SUVN-502 5-HTR6 antagonist 2 Ongoing Geldenhuys and Van der Schyf, 2011/
NCT02580305
Citolapram SSRI 4 weeks Improvement on ADL Nyth and Gottfries, 1990
Fluoxetine SSRI 8 weeks Improvement on MMSE Mowla et al., 2007
Sertraline SSRI 12 weeks Improvement on ADL Lyketsos et al., 2003
ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; CIBIC+, Clinician’s Interview-Based Impression of Change; ADL, Activity of Daily Living; MMSE,
Mini-Mental State Examination; SSRI, Selective Serotonin Reuptake Inhibitor.
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thus far. In the group of the 5-HT1AR, only one PET radioligand,
4-[18F]fluoro-N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-
N-(2-pyridinyl)benzamide ([18F]MPPF, Figure 8), a reversible,
competitive 5-HT1AR antagonist, was investigated in patients
with MCI and AD (Kepe et al., 2006; Truchot et al., 2008).
Decrease of [18F]MPPF binding was noticed in the hippocampus
and raphe nuclei of AD patients (as compared to HCs).
Furthermore, loss of receptor density in the hippocampus was
strongly correlated to a decline in the MMSE score. In patients
with MCI, only a small loss of 5-HT1AR density was noticed,
correlated to only small cognitive decline (Kepe et al., 2006).
[18F]MPPF is one of many fluoro-analogs of [11C]WAY100635,
the latter one being excessively studied in humans. Yet, no
studies on AD patients were performed with [11C]WAY100635,
mainly due its rapid metabolism, making kinetic modeling
difficult (Paterson et al., 2013). [18F]MPPF does not suffer from
these limitations, but is on the other hand a substrate of the P-gp,
which could limit its further use in clinic (Kumar and Mann,
2014). Imaging of the 5-HT2R in AD patients was done by one
SPECT- and three PET radiolabeled 5-HT2R antagonists, namely
4-amino-N-{1-[3-(4-fluorophenyl)propyl]-4-methylpiperidin-4-
yl}-5-[123I]iodo-2-methoxybenzamide ([123I]-R91150), 6-(2-{4-
[4-[18F]fluorobenzoyl]piperidin-1-yl}ethyl)-7-methyl-2H,3H,5H
-[1,3]thiazolo[3,2-a]pyrimidin-5-one ([18F]setoperone), 3-(2-{4-
[4-[18F]fluorobenzoyl]piperidin-1-yl}ethyl)-2-sulfanylidene-1,2,
3,4-tetrahydroquinazolin-4-one ([18F]altanserin) and 3-(2-{4-[4-
[18F]fluorobenzoyl]piperidin-1-yl}(2,2-2H2)ethyl)-2-sulfanylide
ne-1,2,3,4-tetrahydroquinazolin-4-one ([18F]deuteroaltanserin)
(Figure 8). In agreement with previous postmortem studies,
an overall significant reduction in the cerebral cortex was
noted in mild to severe AD patients, compared to their
age-matched controls (Blin et al., 1993; Versijpt et al., 2003;
Santhosh et al., 2009; Marner et al., 2012). In the 5-HT4R class
though, one PET ligand was evaluated on AD patients: [1-
[11C]methylpiperidin-4-yl]methyl 8-amino-7-chloro-2,3-dihy
dro-1,4-benzodioxine-5-carboxylate ([11C]SB207145), a 5-HT4R
antagonist (Figure 8). This radioligand did not display significant
differences between mild AD cases and their HCs, although a
positive correlation was found with the Aβ density (as measured
by [11C]PiB). Moreover, a negative correlation was noticed
between [11C]SB207145’s binding potential and the MMSE
score. Authors suggested that upregulation of 5-HT4R may take
place at a preclinical stage of AD (this in contrast to the other
5-HTRs) and that this may continue through the later AD stages
(Madsen et al., 2011). Finally, (3-amino-4-(2-dimethylamino-
methyl-phenylsulfanyl)-benzonitrile) ([11C]DASB, Figure 8),
a SERT tracer, displayed a more outspoken decrease (25%) of
binding in the subcortical serotonergic projection region in
depressed, as compared to non-depressed AD patients (mean
MMSE score of 18) (Ouchi et al., 2009). Yet, in another clinical
study on patients with mild AD (not corrected for depression)
no such reduction was found (Marner et al., 2012). Authors of
the latter study suggest that this discrepancy may, however, lay in
both differences in dementia severity as well as methodological
differences between these studies (Marner et al., 2012). For a
more detailed discussion about the current state of other 5-HT
PET- and SPECT radioligands, readers are referred to some
excellent reviews (Saulin et al., 2012; Paterson et al., 2013; Billard
et al., 2014; Kumar and Mann, 2014). These compounds can be
used for evaluation of inclusion- and outcome criteria, but also
in dose-occupancy studies.
DOPAMINERGIC SYSTEM
The activity of DA, a catecholamine, is mediated through five
dopaminergic, metabotropic, G-protein coupled receptors. They
are divided into two classes: D1-like receptors (D1R and D5R)
and D2-like receptors (D2−4R), depending on the downstream
signaling cascade. Levels of DA are regulated through the activity
of the presynaptic DAT, which removes DA from the synaptic
cleft to terminate its activity (Mitchell et al., 2011). Dopaminergic
neurons are largely located in the midbrain, with many
projections throughout the brain (Martorana and Koch, 2014),
FIGURE 8 | Structure of serotonergic PET/SPECT tracers.
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where they are involved in various neurological processes. Of
particular importance here is their role in motivation, cognition,
and learning (Xu et al., 2012). Indeed, around 35–40% of AD
patients exhibit extrapyramidal symptoms and more than 70%
display extensive apathy (Lopez et al., 1997; Mitchell et al., 2011).
These symptoms might be explained by the significantly reduced
levels of DA and its precursor L-3,4-dihydroxyphenylalanine (L-
DOPA) (Storga et al., 1996). Although large involvement of DA
in AD is still under debate (Portet et al., 2009; Trillo et al.,
2013), several noticeable changes have been documented in the
DA receptor density. More specifically, a significant reduced
expression of D1- and D2-like receptors has been documented
in the prefrontal cortex and the hippocampus of AD patients
(Kemppainen et al., 2003; Kumar and Patel, 2007). Furthermore,
alterations of the D2R in AD seems positively correlated to
BPSD and verbal memory performance (Kemppainen et al., 2003;
Tanaka et al., 2003). Conflicting results are, however, reported
for the D2R density in AD patients (see further) (Piggott et al.,
1999; Piggott et al., 2007). Contradictory results are also reported
for changes in the DAT levels in AD patients (Murray et al.,
1995; Ceravolo et al., 2004). Despite some discrepancy, it is
clear that there are important DA changes in the AD brains.
Finally, it is to be noted that several in vivo experiments on mice,
expressing AD like pathology, show that significant behavioral
and cognitive deficits can be restored by administering DA
reuptake inhibitors and L-DOPA (Ambree et al., 2009; Guzman-
Ramos et al., 2012). Aβ oligomers may indeed have an early
impact on catecholaminergic transmission (Mura et al., 2010).
There are several modes of interventions toward the failing
dopaminergic system in AD patients, mostly used to address
apathy (the most common BPSD symptom) and extrapyramidal
symptoms. One of many approaches is the use of MAO-B
inhibitors, which are discussed in Section “Monoamine Oxidase
B” of this review. Another therapeutic method is modulation
of the DAT transporter, and thus increasing synaptic DA levels.
This was done by methylphenidate and dextroamphetamine in
several clinical AD studies (Galynker et al., 1997; Herrmann
et al., 2008; Lanctot et al., 2008). Although not selective for
the dopaminergic system, an overall improvement was noted
in symptoms of apathy on the Apathy Evaluation Scale (AES).
There are, however, some concerns about the tolerability of
methylphenidate (Padala et al., 2010). Other drugs that are
frequently used to treat BPSD symptoms in clinical trials (and
routine practice) involving AD patients are the antipsychotic
drugs quetiapine, aripiprazole, olanzapine, and risperidone. As
FDA- and EMA-approved drugs, these drugs act as partial DA
receptor agonist or partial DA receptor antagonist (among often
interaction with many other targets). Overall improvement on
BPSD symptoms was recorded in a large meta-analysis of the
use of antipsychotics in AD patients (Ballard and Waite, 2006).
Nevertheless, caution was advised by the FDA with these drugs,
as they were associated with an increase in risk of death, and
other severe side effects, among elder people with dementia
(Ballard and Waite, 2006; De Deyn et al., 2013). Yet another drug,
rotigotine, a D2R- and D3R agonist, was able to show cognitive
enhancement on probable AD patients, compared to their age-
matched HCs by measuring the cortical excitability and central
cholinergic transmission (Martorana et al., 2013).
Imaging of the dopaminergic system can be done by a
number of PET- and SPECT radioligands. Conflicting results
are, however, reported between several clinical studies on
AD patients, using different PET- and/or SPECT tracers. In a
combined PET study, reduced striatal expression of D1R, but not
D2R was seen with D2R antagonist 3,5-dichloro-N-{[(2S)-1-ethyl
pyrrolidin-2-yl]methyl}-2-hydroxy-6-[11C]methoxybenzamide
([11C]raclopride) and D1R antagonist (5R)-8-chloro-5-(2,3-
dihydro-1-benzofuran-7-yl)-3-[11C]methyl-2,3,4,5-tetrahydro-
1H-3-benzazepin-7-ol ([11C]NNC 756) in AD patients
(Figure 9), compared to age-matched HCs (Kemppainen
et al., 2000). Striatal uptake of 2-amino-3-[2-[18F]fluoro-4,5-
dihydroxyphenyl]propanoic acid ([18F]FDOPA), a fluorinated
form of L-DOPA (Figure 9), was also unchanged in
AD patients, compared to HCs (Tyrrell et al., 1990).
Conversely, decreased striatal expression of D2R with
[11C]raclopride was demonstrated in AD patients (with
BPSD symptoms) as compared to their HCs (Tanaka et al.,
FIGURE 9 | Structure of dopaminergic PET/SPECT tracers.
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2003). Similar studies, using N-{[(2S)-1-ethylpyrrolidin-2-yl]
methyl}-2-hydroxy-3-[123I]iodo-6-methoxybenzamide ([123I]
IBZM) (Figure 9), a D2R antagonist, or methyl (2S,3S)-
3-(4-fluorophenyl)-8-[11C]methyl-8-azabicyclo[3.2.1]octane-2-
carboxylate ([11C]β-CFT) (Figure 9), a cocaine derivative which
binds to DAT, showed, respectively, a reduced expression of
D2R and a reduced DA reuptake (Pizzolato et al., 1996; Rinne
et al., 1998). Reduction of DA reuptake sites, as measured by
[11C]β-CFT, was hereby positively correlated to the severity
of the extrapyramidal symptoms of AD patients, whereas
in the study with [123I]IBZM, patients did not exhibit any
extrapyramidal symptoms. Likewise, a decrease in [18F]FDOPA
striatal uptake was noticed in another study on AD patients,
a decrease which was correlated to the cognitive scores of the
AD patients (Itoh et al., 1994). On the other hand, even more
confusing, is the fact that in yet another clinical study involving
AD patients an increase in D2R expression in the striatum
was now measured with [11C]raclopride (Reeves et al., 2009).
Discrepancies between these different studies might, however,
be explained by different study populations, and the degree
of dementia, since time-dependent dopaminergic receptor
changes were also seen in patients with PD (Brooks, 1993).
Another role for dopaminergic neuroimaging was displayed
by methyl (2S,3S)-8-(3-fluoropropyl)-3-[4-[123I]iodophenyl]-8-
azabicyclo[3.2.1]octane-2-carboxylate ([123I]FP-CIT) (Figure 9),
an analog of [11C]β-CFT. [123I]FP-CIT was able to differentiate,
with high accuracy, patients with AD, and patients with DLB
(Colloby et al., 2008; Spehl et al., 2015). Overall reduced
striatal uptake was noticed in both diseases, but lower binding
potentials of [123I]FP-CIT were reported in DLB than in the
case of the AD patients. These scans can greatly improve
differential diagnosis between the different neurodegenerative
diseases, which often display similar clinical presentations.
[123I]FP-CIT SPECT scans are already used in clinical routine to
distinguish DLB- from AD patients (Spehl et al., 2015). Finally,
5-[3-[18F]fluoropropyl]-2,3-dimethoxy-N-{[1-(prop-2-en-1-yl)
pyrrolidin-2-yl]methyl}benzamide ([18F]fallypride) (Figure 9),
a D2R/D3R antagonist, could be used to assess the ideal
therapeutic window for the use of antipsychotic drugs (Clark-
Papasavas et al., 2014), since, as mentioned before, elder
people are very sensitive to these drugs. [18F]fallypride
PET scans could consequently assist in antipsychotic dose-
occupancy studies, and thus help to provide an ideal
antipsychotic strategy in AD patients with extensive BPSD
symptoms.
NEUROINFLAMMATION
Translocator Protein
Formerly known as PBR, the 18 kDa TSPO, is located on the
outer membrane of the mitochondria, predominantly in glial
cells. As part of a multimeric complex, which is comprised of
a VDAC and an adenine nucleotide carrier (McEnery et al.,
1992; Casellas et al., 2002; Cosenza-Nashat et al., 2009), several
functions are associated with TSPO (Midzak et al., 2015). They
play an essential role in neurosteriod synthesis, by facilitating the
transport of cholesterol from the outer to the inner membrane
of the mitochondria (Papadopoulos et al., 2006a,b), and hence
potentiate the GABAergic neurotransmission through allosteric
modulation of the GABAA receptor by neurosteroids (Belelli
and Lambert, 2005; Hosie et al., 2006; Rudolph and Mohler,
2006). Furthermore, TSPO may have a crucial function in a
variety of cellular processes, such as cell proliferation (Miettinen
et al., 1995; Hardwick et al., 1999), mitochondrial respiration
(Hirsch et al., 1989) and cell apoptosis (Kugler et al., 2008).
In light of TSPO’s association with the pathophysiology of
neurodegenerative diseases, it has been well established that
part of the neurotoxicity caused by tau and Aβ deposits in
AD is induction of a neuroinflammatory response (McGeer
and McGeer, 1995; Hoozemans et al., 2011), which triggers the
upregulation of TSPO in activated microglia and astrocytes.
Moreover, this upregulation clearly correlates with the degree
of neuroinflammation, making TSPO a valuable target for drug
monitoring (Venneti et al., 2006). Interestingly, in a review
by Chua et al. (2014), it was suggested that TSPO ligands
may provide effective tools for treatment of AD through
activation of neuroprotective pathways of increased expression
of astrocytes and microglial cells, since these mechanisms
may have a protective phagocytic role in early AD (Morgan
et al., 2005). Once a more progressed AD state has been
reached, neuroinflammation turns chronic and becomes harmful
(Hickman et al., 2008). This view is in contrast with numerous
clinical trials, using anti-inflammatory drugs that failed to
produce significant improvement in AD patients (Streit, 2010;
Venigalla et al., 2015), although this failure may be attributed
to a ‘wrong’ stage of the disease when therapy was initiated
(Moreira et al., 2006). There are currently no drugs in clinical
trials that interact with the TSPO receptor in AD. Drugs that
are already described are mainly used for their use against BPSD
symptoms (Rupprecht et al., 2009; Owen et al., 2011). TSPO is,
however, an important marker for neuroinflammation, which
makes it an interesting target for neuroimaging. PET tracers
in this class will thus mainly be used to assess inclusion- and
outcome criteria in clinical trials with anti-neuroinflammatory
drugs in AD.
The most studied TSPO tracer in patients with CNS
disorder is without a doubt N-[(2R)-butan-2-yl]-1-(2-chlorophe
nyl)-N-[11C]methylisoquinoline-3-carboxamide ([11C]PK111
95) (Figure 10), despite its low specific binding and minimal
brain uptake (Damont et al., 2013). Nonetheless, conflicting
results are reported with [11C]PK11195, but also with several
other clinical TPSO tracers, such as N-{[2-[11C]methoxy
phenyl]methyl}-N-(4-phenoxypyridin-3-yl)acetamide ([11C]PB
R28), N-(5-fluoro-2-phenoxyphenyl)-N-{[2-[11C]methoxy-5-
methoxyphenyl]methyl}acetamide ([11C]DAA1106), (2-[11C])
ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,708,18.
015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate ([11C]
vinpocetine), N-({2-[2-[18F]fluor-ethoxy]-5-methoxyphenyl}
methyl)-N-[2-(4-methoxyphenoxy)pyridin-3-yl]acetamide ([18F]
FEMPA), N-({2-[2-[18F]fluoroethoxy]-5-methoxyphenyl}methyl)-
N-(2-phenoxyphenyl)acetamide ([18F]FEDAA1106) and N,N-
diethyl-2-(2-{4-[2-[18F]fluoroethoxy]phenyl}-5,7-dimethylpyra
zolo[1,5-a]pyrimidin-3-yl)acetamide ([18F]DPA-714) (Figure 10).
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FIGURE 10 | Structure of TSPO PET tracers.
While a majority of clinical trials was able to show significant
tracer uptake in at least one brain area in AD patients, several
other studies failed to differentiate MCI or even HCs from AD
(Varley et al., 2015; Stefaniak and O’Brien, 2016). Apart from
low signal-to-noise ratios and low brain uptake of some of
these compounds, there are many possible explanations for the
discrepancies in TSPO expression, as measured by PET in these
clinical trials involving AD patients (Janssen et al., 2016). It is,
however, important to realize, as suggested before (Janssen et al.,
2016), that many patients exhibit different TSPO expression
levels, depending on the specific polymorphism in the TSPO
gene, resulting in intersubject variability in the binding affinities
of TSPO PET tracers (Owen et al., 2012). Increasing efforts have
therefore been focused toward compounds that are insensitive
toward TSPO polymorphism, but also toward compounds for
other neuroinflammatory targets (such as MAO-B, see Section
Monoamine Oxidase B). Furthermore, overexpression of TSPO
in both astrocytes and microglial cells make it difficult to
differentiate MCI from AD patients (Ekonomou et al., 2015;
Janssen et al., 2016). Nevertheless, [18F]DPA-714 is currently
being used to assess the degree of neuroinflammation in
AD patients in two clinical trials (CTI: NCT02377206 and
NCT02062099). For a more detailed discussion of the current
status of PET development for TSPO, or neuroinflammation in
general, readers are referred to several other reviews (Ory et al.,
2014; Varley et al., 2015; Janssen et al., 2016).
Monoamine Oxidase B
Monoamine oxidases are mitochondrial bound enzymes, as a
member of the flavin-containing amine oxidoreductases protein
family, in the CNS primarily found in astrocytes. They are
responsible for oxidative deamination of monamines of both
FIGURE 11 | Structure of MAO-B PET tracer.
endogenous and exogenous sources, regulating the physiological
activity of neurotransmitters as serotonin, DA, and noradrenaline
(Strolin and Dostert, 1989). There are two types of isoforms,
MAO-A and MAO-B, which differ in inhibitor sensitivity and
substrate selectivity, although there is an overlap to some degree
(Bortolato et al., 2008). Increased MAO-B activity has been
noted in AD in both brain and blood platelets (Adolfsson et al.,
1980; Alexopoulos et al., 1987; Sparks et al., 1991), the severe
upregulation in the brain mainly being a consequence of a plaque
associated neuroinflammatory response by reactive astrocytes
(Jossan et al., 1991; Saura et al., 1994). Furthermore, during their
catalytic deamination, MAOs produce neurotoxic byproducts
such as hydrogen peroxide, which are one of the main culprits in
oxidative stress, contributing to the formation of amyloid plaques
(Huang et al., 2012; Zheng et al., 2012). Since MAOs play a key
role in the regulation of several important neurotransmitters,
cognitive impairment, due to pathological upregulation of MAOs
has also been demonstrated (Delumeau et al., 1994). MAO
inhibitors may therefore have a significant neuroprotective role
in AD. Since MAO-B is the main isoform present in brain
(Riederer et al., 1978; Sonsalla and Golbe, 1988) and inhibition
of MAO-B proved to be useful as therapeutic approach in PD,
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focus has mainly been targeted toward MAO-B inhibition in
AD (Thomas, 2000). So far, five different drugs have inhibited
MAOs in clinical trials involving AD patients (Cai, 2014).
Two of them, selegiline (L-deprenyl) and rasagiline (Azilect),
irreversible MAO-B selective inhibitors, are established drugs
in the treatment of PD, delaying the need for DA replacement
therapy (Birkmayer et al., 1977; Lees et al., 1977; Weinreb et al.,
2010). While selegiline initially showed promise in clinical trials
involving AD patients, demonstrating modest improvements on
cognitive and behavioral functions (Filip and Kolibas, 1999),
a comprehensive meta-analysis showed no justification for the
use of selegiline in the treatment of AD, since there was a
lack of overall significant benefit (Birks and Flicker, 2003).
The beneficial effect of rasagiline is yet to be evaluated in AD
patients. A Phase II proof of concept trial in patients with mild
to moderate AD is, however, underway (CTI: NCT02359552).
Interestingly, rasagiline formed the basis of two other multi-
target drugs, ladogistil (TV3326), and M-30. The former drug is
a MAO-B inhibitor and AChE inhibitor, the latter a MAO-A and
MAO-B inhibitor (Youdim, 2013). Both compounds are thought
to modulate APP expression levels (by stimulating the non-
amyloidogenic pathway) and both may have neuroprotective
and neurorestorative functions (Riederer et al., 2004; Youdim,
2013). Phase II trials with ladogistil on mild to moderate AD
patients have been completed, but results are yet to be published
(CTI: NCT01354691). These drugs may hold promise as multi-
target approach for treatment of AD, being able to tackle various
pathophysiological changes at once (Youdim, 2013). Finally, EVT
301 (RO4477478), a reversible MAO-B inhibitor was evaluated
on four AD patients (MMSE score: not specified) in a dose-
finding study, using [11C]deprenyl-D2 ([11C]DED) PET (See
further, Figure 11) to assess MAO-B occupancy levels. Seven
days of treatment resulted hereby in an almost complete dose-
occupancy of MAO-B (Hirvonen et al., 2009). No further clinical
trials, to our knowledge, have since been performed with this
drug.
Only one MAO binding PET tracer has been elevated on AD
patients thus far: [11C]methyl[(2R)-1-phenylpropan-2-yl][(1,1-
2H2)prop-2-yn-1-yl]amine ([11C]DED), an irreversible MAO-
B inhibitor (Hirvonen et al., 2009; Carter et al., 2012; Choo
et al., 2014). Increased uptake of [11C]DED was observed in
patients with MCI (who responded positively to a [11C]PIB
scan), suggesting that astrocytocis may be an early event in the
development of AD. Clinical AD studies with other emerging
(fluorine-18 labeled) MAO radiotracers are yet to be published
(Ory et al., 2014; Fowler et al., 2015).
CONCLUSION
This review demonstrates that there are multiple approaches
to be considered when developing disease altering drugs for
AD. Important to notice is that each of these pathways is
linked to the pathophysiological processes of (often many)
other targets, hence a multi-target approach, addressing various
pathophysiological changes at once, will be the way forward.
Concordant neuroimaging techniques, such as PET and SPECT,
could hereby greatly improve therapeutic monitoring, but also
significantly aid with the proposal of current inclusion- and
outcome criteria in large clinical studies. Moreover, once a disease
altering drug has been found, PET/SPECT could eventually be
used as standard test to assess and follow up disease progression
(Barthel et al., 2015). Still, there are a few important factors to
take in consideration. One of them is the need for quantitative
PET assessment, especially during evaluation of novel therapies,
to allow quantitative and accurate evaluations. Visual inspection
or simplified models (such as SUV) are indeed less robust,
as they are influenced by several physiological and technical
factors (Boellaard, 2009; Tomasi et al., 2012). The other side
of the coin is, however, that quantitative PET assessment is
very time-consuming, which limits capacity and throughput
which are essential in large multi-center trials. Another crucial
issue is the loss of BBB function during AD progression, which
could greatly affect drug dosage and bioavailability of novel
AD therapeutics. One way of monitoring the viability of the
BBB is by looking at the P-gp function. Several promising
PET candidates are now under development for this purpose
(Syvanen and Eriksson, 2013), and a pilot study to assess
the P-gp function in AD patients is currently ongoing (ECT:
2013-001724-19). Finally, there is a great need for a thorough
preclinical evaluation of the mechanism of action. This could
not be better demonstrated than by the rise and fall of dimebon.
Initially developed as an antihistaminic drug in the former USSR,
dimebon demonstrated significant improvement on the ADAS-
cog-, MMSE-, and CIBIC+ scales in a 6-month Phase II trial
on AD patients in Russia (Bezprozvanny, 2010). Consequently,
a multi-national Phase III trial was launched, but this trial
failed to show any significant improvement on mild to moderate
AD patients, as compared to placebo (Bezprozvanny, 2010).
In a synopsis by Bezprozvanny (Bezprozvanny, 2010), failure
was largely attributed to poor understanding of the proper
mechanism of action in preclinical studies and the lack of
objective biomarkers to assess the true therapeutic response in
clinical trials. In the last decade, most clinical trials aiming to find
AD combatting drugs ultimately failed to produce (convincing)
positive results. Although there may be many explanations for
this overall failure, thorough preclinical assessment remains an
important factor.
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